Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk ...

Moleculin Biotech shares are trading higher on Wednesday after the company announced the online publication of preclinical ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...

Daiichi Sankyo has announced the dosage of the first subject in the trial of VANFLYTA in adults with newly diagnosed FLT3-ITD negative AML.

The ocean's biodiversity is a key source of marine-derived compounds, fueling pharmaceutical innovations and drug discovery ...

The first patient has been dosed in the QuANTUM-Wild phase 3 trial evaluating Daiichi Sankyo’s (TSE: 4568) VANFLYTA® ...

Early disease detection is beneficial for securing the best possible outcomes for patients. But finding noninvasive, ...

Molecular Cellular Pharmacology Graduate Program, University of Wisconsin-Madison, Madison, USA Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan ...

Early disease detection is beneficial for securing the best possible outcomes for patients. But finding noninvasive, ...

News from the American Heart Association 2024 Scientific Sessions took seven of the 10 top slots this month.